GBP1 promotes non-small cell lung carcinoma malignancy and chemoresistance via activating the Wnt/ β-catenin signaling pathway.

CONCLUSIONS: In our study, GBP1 was firstly identified as a novel oncogene in NSCLC. Furthermore, it could promote NSCLC development and paclitaxel resistance by inducing Wnt/β-catenin signaling pathway. PMID: 32495881 [PubMed - in process]
Source: European Review for Medical and Pharmacological Sciences - Category: Drugs & Pharmacology Tags: Eur Rev Med Pharmacol Sci Source Type: research